JAPAN’S PHARMA RENAISSANCE AND WHAT YOU NEED TO KNOW

A Blueprint for Global Partnerships

(日本語は英語の後に続く)

As the much lauded Nikkei Drug Development Ecosystem Summit convenes today at the Grand Hyatt Tokyo, a palpable momentum is building within Japan's life sciences sector. For decades, Japan has been perceived by many as a risk-averse, internally focused pharmaceutical market. However, a profound transformation is underway, repositioning the nation as a dynamic engine of innovation. From the cutting edge of AI-driven trial optimisation to pioneering regulatory fast-tracking, Japan is systematically re-engineering its drug development landscape. This strategic overhaul isn't just about domestic growth; it's a clear invitation for deeper, more impactful global collaboration.